Gilead Sciences to acquire Kite Pharma for $11.9bn
29-08-2017
CIPhotos / iStockphoto.com
Pfizer has revealed its plan to take a 25% stake in Allogene Therapeutics to further develop Pfizer’s allogeneic chimeric antigen receptor T cell (CAR T) therapy.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Pfizer, Allogene Therapeutics, cancer, oncology, Kite Pharma, CAR T therapy, collaboration